Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transcend Therapeutics' Procysteine to enter Phase III for ARDS in early 1997 -- IPO prospectus.

Executive Summary

TRANSCEND THERAPEUTICS PROCYSTEINE TO ENTER PHASE III TRIALS for treatment of acute respiratory distress syndrome in the first quarter of 1997, the company forecasts in an Aug. 22 prospectus for an initial public offering. Procysteine treats diseases associated with oxidative damage, the prospectus states, describing it as "a system for introducing into cells the amino acid cysteine, an essential building block of glutathione," one of the body's principal mechanisms for neutralizing the highly reactive toxic molecules known as reactive oxygen species, according to Transcend.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel